IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Arms / Cohorts
Experimental:Phase 1: IDP-023 (Single Dose)
Accepting patients
Experimental:Phase 1: IDP-023 (Multiple Doses)
Accepting patients
Experimental:Phase 1: IDP-023 + IL-2
Accepting patients
Experimental:Phase 2: IDP-023 + Rituximab
Not yet accepting
Experimental:Phase 2: IDP-023 + Daratumumab
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.